Literature DB >> 2453507

Generation and characterization of peptide-specific antibodies that inhibit von Willebrand factor binding to glycoprotein IIb-IIIa without interacting with other adhesive molecules. Selectivity is conferred by Pro1743 and other amino acid residues adjacent to the sequence Arg1744-Gly1745-Asp1746.

S Berliner1, K Niiya, J R Roberts, R A Houghten, Z M Ruggeri.   

Abstract

We have generated antibodies against a synthetic peptide corresponding to the sequence of human von Willebrand factor (vWF) between residues Glu1737-Ser1750 which includes the Arg-Gly-Asp sequence common to several adhesive molecules. Two anti-peptide antibodies, one polyclonal, and one monoclonal reacted with native vWF and inhibited its binding to platelet glycoprotein (GP) IIb-IIIa, but showed negligible cross-reactivity with fibrinogen, fibronectin, and vitronectin, three other molecules that contain the sequence Arg-Gly-Asp and bind to platelets. The structural bases for the specificity of the two antibodies were evaluated by testing the ability of peptides homologous to the parent sequence, but with single amino acid substitutions, to neutralize the binding of the two antibodies to vWF. The substitution of Pro1743, the residue immediately adjacent to the Arg-Gly-Asp sequence on the amino-terminal side, with Phe resulted in a peptide that failed to interact with either antibody. Thus, Pro1743 is important for maintaining a peptide conformation recognized by two antibodies specific for the GP IIb-IIIa-binding domain of vWF. Other residues important for optimal peptide reactivity with the polyclonal antibody were Ser1742, Arg1744, and Gly1745, whereas Gly1741, Gly1745, and Asp1746, but not Arg1744, were important for reactivity with the monoclonal antibody. The epitopes of both antibodies, therefore, included at least 2 of the residues in the sequence Arg-Gly-Asp considered the common cell-binding site of adhesive molecules that interact with GP IIb-IIIa. Nevertheless, both antibodies reacted only with vWF. These studies demonstrate that peptide-specific antibodies, unlike the promiscuous GP IIb-IIIa receptor, can recognize distinctive structural characteristics of the cell-binding domain of adhesive molecules imposed by residues adjacent to the sequence Arg-Gly-Asp.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2453507

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Distinct abnormalities in the interaction of purified types IIA and IIB von Willebrand factor with the two platelet binding sites, glycoprotein complexes Ib-IX and IIb-IIIa.

Authors:  L De Marco; M Mazzucato; D De Roia; A Casonato; A B Federici; A Girolami; Z M Ruggeri
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

2.  The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress.

Authors:  Y Ikeda; M Handa; K Kawano; T Kamata; M Murata; Y Araki; H Anbo; Y Kawai; K Watanabe; I Itagaki
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

3.  Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor.

Authors:  J A Dent; S D Berkowitz; J Ware; C K Kasper; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

4.  Affinity of Fibrinogen Binding to Platelet Membrane Glycoprotein IIb/IIIa Increases with RGDS and gamma Chain Fibrinogen Peptide Hybrid.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

5.  Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations.

Authors:  Jeffrey J Sutherland; Lee A O'Brien; David Lillicrap; Donald F Weaver
Journal:  J Mol Model       Date:  2004-08-03       Impact factor: 1.810

6.  Epitope mapping by cDNA expression of a monoclonal antibody which inhibits the binding of von Willebrand factor to platelet glycoprotein IIb/IIIa.

Authors:  G Piétu; A S Ribba; G Chérel; D Meyer
Journal:  Biochem J       Date:  1992-06-15       Impact factor: 3.857

7.  Von Willebrand factor promotes endothelial cell adhesion via an Arg-Gly-Asp-dependent mechanism.

Authors:  E Dejana; M G Lampugnani; M Giorgi; M Gaboli; A B Federici; Z M Ruggeri; P C Marchisio
Journal:  J Cell Biol       Date:  1989-07       Impact factor: 10.539

8.  The von Willebrand factor Tyr2561 allele is a gain-of-function variant and a risk factor for early myocardial infarction.

Authors:  Reinhard Schneppenheim; Natalie Hellermann; Maria A Brehm; Ulrike Klemm; Tobias Obser; Volker Huck; Stefan W Schneider; Cécile V Denis; Alexander Tischer; Matthew Auton; Winfried März; Emma-Ruoqi Xu; Matthias Wilmanns; Rainer B Zotz
Journal:  Blood       Date:  2018-10-26       Impact factor: 25.476

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.